Yale School of Medicine: New Research Sheds Light on Equitable Treatment Options for Pediatric Patients With Sickle Cell Disease
December 07, 2023
December 07, 2023
NEW HAVEN, Connecticut, Dec. 7 (TNSres) -- The Yale University School of Medicine issued the following news:
By Michael Masciadrelli
Patients with sickle cell disease (SCD) often face a reduced quality of life and a lower life expectancy. Allotransplantation, the first treatment for SCD with curative potential, comes with risks, including transplant-related mortality. Gene therapy, once approved for SCD, could also offer a lifelong cure without the risk associated with . . .
By Michael Masciadrelli
Patients with sickle cell disease (SCD) often face a reduced quality of life and a lower life expectancy. Allotransplantation, the first treatment for SCD with curative potential, comes with risks, including transplant-related mortality. Gene therapy, once approved for SCD, could also offer a lifelong cure without the risk associated with . . .